Department of Cell and Molecular Biology, QIMR Berghofer Medical Research Institute, Herston, QLD, Australia.
Ningxia Center for Disease Control and Prevention, Ningxia, China.
Commun Biol. 2021 May 11;4(1):557. doi: 10.1038/s42003-021-02064-7.
Dengue virus (DENV) is spread from human to human through the bite of the female Aedes aegypti mosquito and leads to about 100 million clinical infections yearly. Treatment options and vaccine availability for DENV are limited. Defective interfering particles (DIPs) are considered a promising antiviral approach but infectious virus contamination has limited their development. Here, a DENV-derived DIP production cell line was developed that continuously produced DENV-free DIPs. The DIPs contained and could deliver to cells a DENV serotype 2 subgenomic defective-interfering RNA, which was originally discovered in DENV infected patients. The DIPs released into cell culture supernatant were purified and could potently inhibit replication of all DENV serotypes in cells. Antiviral therapeutics are limited for many viral infection. The DIP system described could be re-purposed to make antiviral DIPs for many other RNA viruses such as SARS-CoV-2, yellow fever, West Nile and Zika viruses.
登革热病毒（DENV）通过雌性埃及伊蚊的叮咬在人与人之间传播，每年导致约 1 亿例临床感染。目前针对 DENV 的治疗选择和疫苗有限。缺陷干扰颗粒（DIP）被认为是一种很有前途的抗病毒方法，但传染性病毒污染限制了它们的发展。本研究开发了一种源自 DENV 的 DIP 生产细胞系，该细胞系可连续产生无 DENV 的 DIP。DIP 包含并可将 DENV 血清型 2 亚基因组缺陷干扰 RNA 递送至细胞，该 RNA 最初在感染 DENV 的患者中被发现。释放到细胞培养上清液中的 DIP 被纯化，可有效抑制细胞中所有 DENV 血清型的复制。目前针对许多病毒感染的抗病毒疗法有限。所描述的 DIP 系统可被重新用于制造针对许多其他 RNA 病毒（如 SARS-CoV-2、黄热病、西尼罗河和寨卡病毒）的抗病毒 DIP。
